Drug Trial Radar · NCT07613359
A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Oct 27, 2026
Primary completion
Jan 15, 2029
Study completion Jan 15, 2029
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- May 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Antibody-mediated rejection (AMR) is a major cause of worsening kidney function after a kidney transplant (kidney allograft dysfunction) and can lead to kidney failure. AMR happens when the kidney recipient's immune system makes antibodies that attack the donor kidney. Antibodies are proteins made by the immune system to recognize foreign cells. Over time, this attack can damage kidney tissue and cause the transplant to fail. Because AMR can be serious, there is a need for treatments that are safe, work well, and are supported by good evidence. The main aim of this study is to find out how safe mezagitamab is and how well adults with AMR tolerate it compared with placebo. A placebo looks like medicine but has no active ingredients. The study will also look at whether mezagitamab helps to control inflammation in the transplanted kidney and helps keep kidney function stable, compared with placebo. Participants will be placed by chance in 1 of the 3 treatment groups in equal numbers. Two groups will receive mezagitamab in two different doses. One group will receive placebo. This means that out of every 3 participants, 2 will receive mezagitamab and 1 will receive placebo. During the study, participants will visit their study clinic several times.
Conditions
- Antibody-Mediated Rejection (AMR)
Interventions
MezagitamabDrug
Mezagitamab subcutaneous (SC) injection.
PlaceboDrug
Mezagitamab-matching placebo SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Arms A, B, and C: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to Week 70
- Arms A, B, and C: Number of Participants With Related TEAEsTime frame: Up to Week 70
- Arms A, B, and C: Number of Participants With Serious Adverse Events (SAEs)Time frame: Up to Week 70
- Arms A, B, and C: Number of Participants With AEs of Special InterestTime frame: Up to Week 70
- Arms A, B, and C: Number of Participants With AE Leading to Treatment DiscontinuationTime frame: Up to Week 70
- Arms A, B, and C: Number of Participants With Clinically Significant Abnormal Laboratory Test Results and Vital SignsTime frame: Up to Week 70
Locations
35 sites in 5 countries. Site status is shown where the registry gives one.
UCLA University of California Los Angeles
Los Angeles, California · Not yet recruiting
Kaiser Permanente-San Francisco Medical Center - Kidney Transplant Clinic
San Francisco, California · Not yet recruiting
University of Miami Hospital and Clinics
Miami, Florida · Not yet recruiting
Tampa General Hospital
Tampa, Florida · Not yet recruiting
University of Maryland
Baltimore, Maryland · Recruiting
Washington University School of Medicine
St Louis, Missouri · Not yet recruiting
Cooperman Barnabas Medical Center
Livingston, New Jersey · Recruiting
NYU Langone Health - Transplant Associates
New York, New York · Not yet recruiting
Weill Cornell Medicine - Nephrology and Kidney Transplantation Medicine
New York, New York · Not yet recruiting
Cleveland Clinic - Cleveland
Cleveland, Ohio · Not yet recruiting
University of Texas Southwestern Medical Center
Dallas, Texas · Not yet recruiting
Intermountain Healthcare
Murray, Utah · Not yet recruiting
Virginia Commonwealth University (VCU) - Medical Center - Hume-Lee Transplant Center (HLTC)
Richmond, Virginia · Not yet recruiting
Froedtert and The Medical College of Wisconsin
Milwaukee, Wisconsin · Not yet recruiting
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China · Not yet recruiting
The First Affiliated Hospital of Sun Yat-sen University
Guangdong, Guangdong, China · Not yet recruiting
The Second Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China · Not yet recruiting
Tongji Hospital Affiliated to Tongji Medicine University
Wuhan, Hubei, China · Not yet recruiting
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China · Not yet recruiting
Shandong Provincial Qianfoshan Hospital
Jinan, Shandong, China · Not yet recruiting
West China Hospital Sichuan University
Chengdu, Sichuan, China · Not yet recruiting
The First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Not yet recruiting
CHU Bordeaux, CHU Pellegrin
Bordeaux, France · Not yet recruiting
Hopital Henri Mondor
Créteil, France · Not yet recruiting
Hopital Edouard Herriot (HEH)
Lyon, France · Not yet recruiting
CHU de Toulouse - Hopital Rangueil
Toulouse, France · Not yet recruiting
Ludwig-Maximilians-Universitaet Muenchen (LMU) Klinikum der Universitaet Muenchen
München, Germany · Not yet recruiting
Universitaetsklinikum Muenster
Münster, Germany · Not yet recruiting
Kliniken Universitatsklinikum Bochum GmbH
Bochum, North Rhine-Westphalia, Germany · Not yet recruiting
Universitaetsklinikum Essen
Essen, North Rhine-Westphalia, Germany · Not yet recruiting
Niigata University Medical and Dental Hospital
Niigata, Japan · Not yet recruiting
Osaka Metropolitan University Hospital
Osaka, Japan · Not yet recruiting
Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital
Nagoya, Aichi-ken, Japan · Recruiting
Japanese Red Cross Kumamoto Hospital
Kumamoto, Kumamoto, Japan · Recruiting
Yochomachi Clinic
Shinjuku-ku, Tokyo, Japan · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.